BioLab
Yale School of Medicine, Kim Lab
김지연 교수
- 등록2024.09.09
- 조회2275
연구실 소개
연구실 홈페이지암세포는 정상 세포와는 다르게 빠르게 자랍니다. 따라서, Energy production, Building block synthesis 그리고 Antioxidant defense mechanism이 다르게 나타납니다. 이를 Metabolic reprogramming 또는 Metabolic alteration이라고 합니다. 이로인해, 정상 세포와는 다르게 암세포는 특정 대사 경로에 의존하게 되고, 이를 이용하여 암치료에 응용할 수 있습니다.
저희 랩에서는 암세포가 의존하는 대사 경로를 찾고, 그 경로 안의 유전자 및 단백질을 표적으로 하여, 정 상세포의 생존에는 문제가 없고, 암 세포만을 특이적으로 죽이는 연구를 하고 있습니다.
Jiyeon Kim, Ph.D. (김지연)
Assistant Professor, Dept. of Urology and Dept. of Cellular & Molecular Physiology, Yale School of Medicine
EDUCATION
2012-2018 Postdoctoral Fellow, UT-Southwestern Medical Center, Dallas, TX
2007-2012 Ph.D. in Molecular Cancer Biology, Duke University, Durham, NC
2005-2007 M.S. in Biochemistry, Chungbuk National University, Cheongju, South Korea
1999-2003 B.S. in Biology (First in class), Yonsei University, Seoul, South Korea
EMPLOYMENT
11.2022 - present Assistant Professor, Dept. of Urology and Cellular & Molecular Physiology, Yale School of Medicine
08.2018 - 10.2022 Assistant Professor, Dept. of Biochemistry and Molecular Genetics, Universiy of Illinois at Chicago
연구분야
Dr. Kim is a basic research scientist in the Department of Urology with a joint appointment in the Department of Cellular and Molecular Physiology. She received her PhD from the Department of Molecular Cancer Biology at Duke University under the supervision of Dr. Sally Kornbluth, and her postdoctoral training from Dr. Ralph DeBerardinis at UT-Southwestern Medical Center. Before coming to Yale, she was The Kim lab is focused on understanding how metabolic alterations elicit dependencies and liabilities in certain signaling pathways and how we can target the pathway as cancer’s Achilles' heel.
The lab has been actively applying metabolic flux analysis to panels of cancer cell lines with various mutations to understand the full breadth of metabolic diversity in cancer. These studies are complemented by in vivo analyses of cancer metabolism in mice, and by translational efforts designed to understand and exploit the metabolic idiosyncrasies of tumor cells.
연구성과
Selected Publication
2022
A new role for ammonia in tumorigenesis?
Lee HM, Nayak A, Kim J. A new role for ammonia in tumorigenesis? Cell Metab 2022, 34: 944-946. PMID: 35793658, DOI: 10.1016/j.cmet.2022.06.009.
Commentaries, Editorials and Letters
Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer.
Lee H, Cai F, Kelekar N, Velupally NK, Kim J. Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer. Cells 2022, 11 PMID: 35011738, DOI: 10.3390/cells11010176.
Peer-Reviewed Original Research
2020
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab 2020, 2: 1401-1412. PMID: 33257855, DOI: 10.1038/s42255-020-00316-0.
Peer-Reviewed Original Research
Amino acids in cancer.
Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med 2020, 52: 15-30. PMID: 31980738, DOI: 10.1038/s12276-020-0375-3.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
연구실 구성원
지도교수 : 김지연
(2024 현재)
Ph.D. : 이현민
Contact: jiyeon.kim1@yale.edu
Homepage: https://medicine.yale.edu/profile/jiyeon-kim1/
하고싶은 이야기
본 정보는 해당 기관에서 제공한 자료를 바탕으로 구성된 내용으로, BRIC에서 자체 생산한 정보가 아님을 밝혀드립니다.
소개된 내용에서 중요하게 판단되는 부분은 해당 기관에 추가적으로 사실 확인 작업을 하시길 부탁드립니다.
내용의 업데이트 또는 변경을 원하시면 관리자(interview@ibric.org)에게 연락 바랍니다.
